Neurovascular Devices – Market Insights – Japan

The Japanese neurovascular device market will experience moderate growth through 2034. This update reflects the impact of recent developments, including the launch of new-generation devices and emerging clinical data supporting procedures such as middle meningeal artery embolization. The continued adoption of innovative devices and Japan’s large aging population will also lead to rising neurovascular procedures.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for neurovascular devices in Japan from 2019 through 2034.

Emergence of evidence supporting use of embolization devices in the treatment of chronic subdural hematoma will support growth of neurovascular embolization procedures.

Which embolization devices will experience the highest adoption rates in the management of chronic subdural hematoma?

Which companies are positioned to gain the most in terms of market share?

What implications will the adoption of embolization procedures for chronic subdural hematoma have on the neurovascular embolization device market in Japan?

Which ongoing clinical trials will decide the treatment options for chronic subdural hematoma?

What is the expected impact of these clinical trials on overall embolization space?

New technologies in the thrombectomy device market are influencing the adoption of thrombectomy for AIS.

What new devices have entered the Japanese market in recent years, and what others are anticipated to enter the Japanese market within the forecast period?

How have market shares been shifting with the introduction of new products?

What challenges will new companies encounter in this space? Will they capture significant share from existing competitors?

What emerging technologies are currently under evaluation in clinical trials?

Flow-diverting devices and liquid embolics are contributing to growth in the neurovascular embolization device market.

How will the adoption of flow-diverting devices change the neurovascular embolization coil and coiling-assist device markets?

How will the liquid embolic market change in the coming years?

What clinical trial results are impacting the liquid embolic space?

Clinical data will play an important role in driving the adoption of neurovascular devices.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on market dynamics?